Success Metrics

Clinical Success Rate
92.5%

Based on 37 completed trials

Completion Rate
93%(37/40)
Active Trials
2(5%)
Results Posted
43%(16 trials)
Terminated
3(7%)

Phase Distribution

Ph phase_1
2
5%
Ph not_applicable
5
11%
Ph phase_3
9
20%
Ph phase_4
16
36%
Ph phase_2
11
25%

Phase Distribution

2

Early Stage

11

Mid Stage

25

Late Stage

Phase Distribution43 total trials
Phase 1Safety & dosage
2(4.7%)
Phase 2Efficacy & side effects
11(25.6%)
Phase 3Large-scale testing
9(20.9%)
Phase 4Post-market surveillance
16(37.2%)
N/ANon-phased studies
5(11.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.2%

37 of 41 finished

Non-Completion Rate

9.8%

4 ended early

Currently Active

2

trials recruiting

Total Trials

44

all time

Status Distribution
Active(2)
Completed(37)
Terminated(4)
Other(1)

Detailed Status

Completed37
Terminated3
Withdrawn1
Active, not recruiting1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
44
Active
2
Success Rate
92.5%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (4.7%)
Phase 211 (25.6%)
Phase 39 (20.9%)
Phase 416 (37.2%)
N/A5 (11.6%)

Trials by Status

completed3784%
terminated37%
withdrawn12%
active_not_recruiting12%
recruiting12%
unknown12%

Recent Activity

Clinical Trials (44)

Showing 20 of 44 trialsScroll for more
NCT01103206Phase 4

Evaluation of a Cincalcet Suppression Test

Completed
NCT07122401Phase 3

Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

Recruiting
NCT03994172Phase 4

Novel Combination Therapy for Osteoporosis in Men

Active Not Recruiting
NCT02133404Phase 2

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Completed
NCT02227264Not Applicable

Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?

Completed
NCT05926570Phase 4

Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis

Completed
NCT05663411Phase 2

A Study of SHR6508 in Secondary Hyperparathyroidism

Unknown
NCT02525796Phase 2

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Completed
NCT02440581Not Applicable

Renal Osteodystrophy: An Individual Management Approach

Completed
NCT00345839Phase 3

E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events

Completed
NCT01447368Phase 4

Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients

Completed
NCT03299244Phase 3

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

Completed
NCT01011114Not Applicable

Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant

Terminated
NCT00195936Phase 1

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

Completed
NCT00844740Not Applicable

Calcimimetics in Hypophosphatemic Rickets

Withdrawn
NCT02341417Phase 3

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

Completed
NCT01290029Phase 1

Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease

Completed
NCT01896232Phase 3

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Completed
NCT03776058Phase 2

Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)

Completed
NCT03774771Phase 2

Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism

Completed

Drug Details

Intervention Type
DRUG
Total Trials
44